GlassScriptPhysician profile
Peyman Nazmi
NPI 1891787354
$2,662.17
in general payments reported to CMS, 2019-2025
17 companies · $10.36 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $99.92 · 2021: $721 · 2022: $465 · 2023: $140 · 2024: $482 · 2025: $10.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $932.72 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Medtronic USA, INC. | $512.00 | 2019-2020 | |
| Medtronic, INC. | $452.69 | 2021-2024 | Intellis Adaptivestim |
| Stryker Corporation | $183.71 | 2021-2022 | |
| Orthofix Medical, INC. | $119.37 | 2019 | |
| Scilex Pharmaceuticals INC. | $97.43 | 2019-2022 | |
| Electronic Waveform Lab, INC. | $65.19 | 2019 | |
| Si-Bone, INC. | $46.66 | 2022 | |
| Merz North America, INC. | $42.02 | 2019 | |
| Abbott Laboratories | $39.70 | 2024 | Proclaim |
| Pacira Pharmaceuticals Incorporated | $39.22 | 2022-2023 | Iovera, Zilretta |
| Nevro Corp. | $36.95 | 2021-2022 | |
| Amgen INC. | $29.28 | 2021-2023 | Prolia, Evenity |
| Spr Therapeutics, INC | $20.71 | 2022 | |
| Avanos Medical | $20.07 | 2023 | Coolief* Cooled Radiofrequency |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $14.09 | 2021 | |
| Mml US, INC. | $10.36 | 2025 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyman Nazmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.